RxDoctor Payments Data

Beata Pazdan, MD

Family Medicine · Flemington, NJNPI 1184121469

Payments from drug & device makers

$530in general payments, 2019–2025

Across 13 payments — averaging $40.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$206
  • AstraZeneca$166
  • Medtronic$70
  • Novo Nordisk$37
  • Merck$18
  • Lilly USA, LLC$17
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$530100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK2$206
AstraZeneca4$166
Medtronic2$70
Novo Nordisk2$37
Merck1$18
Lilly USA, LLC1$17
Pfizer1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$530 in reported general payments places this provider in the 50th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$84,277
Medicare patients
363
Services billed
1,035

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide46$51,126
JardianceEmpagliflozin33$33,290
EliquisApixaban18$18,210
VivitrolNaltrexone Microspheres11$17,818
FarxigaDapagliflozin Propanediol13$9,614
Breo ElliptaFluticasone/Vilanterol13$4,997
SynthroidLevothyroxine Sodium68$4,071
Levothyroxine Sodium236$3,750
Atorvastatin Calcium294$2,942
Rosuvastatin Calcium111$2,043
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$1,849
Omeprazole87$1,644
Amlodipine Besylate219$1,540
Metoprolol Succinate90$1,331
Allopurinol51$1,287

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$37$51,12646 claims
PfizerEliquis$15$18,21018 claims
AstraZenecaFarxiga$166$9,61413 claims
GSKBreo Ellipta$206$4,99713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Flemington

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →